It has already been shown that KR can be a potential drug in personalized therapy of CLL [70], while in vivo experiments on mice have also been performed, indicating its anticancer properties, especially for human malignancies with dysregulation of cyclin D1 or D2 [79,110]. Here, CCND1 is linked to B-cell chronic lymphocytic leukemia.